Medical
-
According to Medical Developments International (MVP), the FDA has lifted a clinical hold on MVP’s Penthrox methoxyflurane inhaler and, as a result, MVP is now preparing a Phase 3 trial of Penthrox for trauma pain… Read more . . .
-
Sorrento Therapeutics announced that the FDA has given the company the okay to move ahead with a Phase 1 trial of its Covishield (STI-9199) intranasal antibody cocktail in healthy volunteers. According to Sorrento, in vitro… Read more . . .
-
BlueWillow Biologics and Medigen Vaccine Biologics Corporation (MVC) have announced that a preclinical study of their BW-1019 intranasal COVID-19 booster demonstrated that giving the nasal vaccine after intramuscular vaccination induced neutralizing antibodies and protected against disease in… Read more . . .
-
Non-profit pharma company Harm Reduction Therapeutics (HRT) said that a Phase 1 clinical trial of its HRT001 naloxone nasal spray in healthy volunteers met its primary endpoint, demonstrating the bioequivalence of a 3.0 mg dose… Read more . . .
-
The COPD Foundation has partnered with ENA Respiratory for development of ENA’s INNA-051 pegylated TLR2/6 agonist pan-antiviral nasal spray in patients with chronic lung disease, the company said. In June 2021, ENA Respiratory announced that… Read more . . .
-
TFF Pharmaceuticals said that in vitro studies have demonstrated that the company’s inhaled niclosamide candidate completely inhibits the Omicron variant of SARS-CoV-2 at a concentration of 1 μM, noting that both nirmatrelvir (Paxlovid) and molnupiravir have been… Read more . . .
-
AstraZeneca has announced a partnership with Honeywell for development of lower global warming potential MDIs using HFO-1234ze as a propellant. The company said that Breztri budesonide/ glycopyrronium/ formoterol fumarate is the first product it plans… Read more . . .
-
According to Armata Pharmaceuticals, the FDA has cleared the company’s IND for a clinical trial of AP-PA02, an inhaled phage cocktail, in non-cystic fibrosis bronchiectasis (NCFB), and the company plans to initiate a Phase 2… Read more . . .
-
Virpax Pharmaceuticals said that preclinical studies of the company’s Envelta (NES100) enkephalin nasal spray have not identified any toxicology issues in either rats or dogs. The company said that the results support further development of… Read more . . .
-
Celltrion Group announced that it has submitted an IND application for a Phase 3 trial of an inhaled COVID-19 antibody cocktail for the treatment of mild-to-moderate COVID-19. In July 2021, Celltrion announced that it had… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland